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Statistical Comments
I would like to make statistical comments about the
article by Dyfrig Hughes, “Methods for integrating
medication compliance and persistence in pharmaco-
economic evaluations” (Value in Health 2007;10:498–
509).
In page 9 they wrote an equation for the net mone-
tary beneﬁt of a drug in patient i and described their
net-beneﬁt regression as follows: “The advantage of
this approach is that the impact of compliance on
cost-effectiveness may be assessed at an individual
patient level, thereby providing a robust estimate of
population cost-effectiveness together with fully char-
acterized uncertainty.” Their regression model treats
that all patient data are independent and did not con-
sider the correlation within a cluster or speciﬁc group
with some inﬂuential factors such as age, compliance,
and so on. Their model is thus patient-averaged and
not population-averaged and cannot properly provide
the estimate of population cost-effectiveness. If they
want to refer to the population, they must use gener-
alized estimating equation or other methods to treat
the correlated data. If the authors believe that their
patient-average model can refer to the population cost-
effectiveness, they need to mention the methodology
clearly and to explain the reason why the correlation is
unnecessary to consider. In addition, the formula for
net-beneﬁt regression at page 9 is unclear whether it
refers to the full model or selected model. If the
authors want to say that the selected model is best,
they must show -2 ¥ log likelihood ratio and the chi-
square statistics.
In page 9 the authors described, “There are,
however, certain disadvantages to the net-beneﬁt
regression model, and these include the fact that both
costs and outcomes are analyzed concurrently. Greater
powermay be afforded by explaining cost and effective-
ness separately.” The authors may not consider the fact
that the cost and effectiveness may have a correlation
and they therefore need to be analyzed concurrently. If
the authors want to insist that the separate analysis
gives more power, they should explain their deﬁnition
of the power and the statistical (mathematical) proof.
I have other questions in Figure 1 about their
Markov model. Below the death state there is a circle
indicating a recursive process. As a patient cannot die
many times, this is obviously incorrect. According to
this schema, all patients move from remissive to death
directly or via progressive and cannot return from
progressive to remissive. The authors put a recursive
process to remissive and progressive states and this
indicates that they treated that remissive was a better
health state than progressive. If yes, the model must
consider the returning process from progressive to
remissive and the authors should explain these points.
They did not provide a transition probability
matrix and the mathematical grounds are completely
unclear for the calculation of probabilities in table 2. It
is uncertain whether the authors considered the fact
that a rate needs to be converted into a probability
since a risk is a probability but a rate is not. Note that
the rate or incidence can be larger than one. Miller and
Homan published a concise review about this issue [1].
For example, the estimate of persistence in Table 2
looks a rate and it is not certain whether this rate was
converted into a probability that persistence occurs
within a year. In addition, their calculation procedures
for their Markov model are very unclear. The calcula-
tions for the Markov model probably needed special
software. The authors should provide the name of
software and the transition probability matrix to the
readers in this journal for further inspection. The cal-
culations for nine transition probabilities in their prob-
ability matrix must statistically be justiﬁed and it is
also necessary to make clear the calculation procedures
to obtain Figures 2, 3, and 4 that should be the results
of a Markov model analysis (random walking), not of
a decision tree analysis.––T. Kikushi, PhD, Department
of Statistics, University of Oxford, Oxfordshire, UK.
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